Altimmune Receives 'Moderate Buy' Rating from Analysts

Analysts see potential in the biotech company's pipeline despite recent stock decline

Apr. 2, 2026 at 6:13am

Got story updates? Submit your updates here. ›

Altimmune, Inc. (NASDAQ:ALT) has received a 'Moderate Buy' consensus rating from the 10 analysts covering the company, according to Marketbeat Ratings. The analysts' average 12-month price target for the stock is $18.00.

Why it matters

Altimmune is a clinical-stage biotech company focused on developing vaccines and immunotherapies. Its stock has seen volatility in recent months, making the analyst consensus an important signal for investors about the company's future prospects.

The details

The analyst ratings break down as follows: two 'sell' recommendations, one 'hold', and seven 'buy' recommendations. Several firms have adjusted their price targets for Altimmune, with B. Riley Financial lowering its target to $13.00 and HC Wainwright increasing its target to $25.00.

  • Altimmune reported its latest quarterly results on March 5, 2026.

The players

Altimmune, Inc.

A clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, focused on developing vaccines and immunotherapies.

B. Riley Financial

An investment firm that covers Altimmune and recently lowered its price target on the stock.

HC Wainwright

An investment firm that covers Altimmune and recently increased its price target on the stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain cautious on Altimmune given the volatility in the stock and the competitive landscape for its pipeline.”

— Analyst

“Altimmune's intranasal vaccine technology and metabolic disorder programs present significant long-term potential.”

— Analyst

What’s next

Investors will be closely watching Altimmune's progress on its pipeline programs and any updates from the company on its strategic direction.

The takeaway

While Altimmune's stock has seen volatility, the 'Moderate Buy' consensus from analysts suggests they see promise in the company's vaccine and immunotherapy technologies, though concerns remain about the competitive landscape.